Infinity Bio

Executive Summary

Infinity Bio is a San Diego-based biotechnology company specializing in high-throughput antibody profiling using its proprietary MIPSA technology. By decoding the complete antibody-antigen interaction network—the 'reactome'—the company provides detailed immune system analysis for research in immunology, infectious disease, autoimmunity, and oncology. Its services enable biomarker discovery, vaccine development, and precision medicine, positioning it as a key enabler in the rapidly growing antibody discovery market. Founded in 2019, the company is privately held and has not disclosed funding or valuation details, but its technology addresses a critical bottleneck in characterizing immune responses at scale. With applications ranging from infectious disease surveillance to cancer immunotherapy, Infinity Bio has the potential to become a foundational platform for immunology research and diagnostics. The company's ability to offer comprehensive antibody profiling sets it apart from conventional methods, offering speed and depth that could accelerate therapeutic development and clinical decision-making. As the demand for personalized medicine and immune-based therapies grows, Infinity Bio is well-positioned to capture value by providing essential data and insights to pharmaceutical and academic partners. However, as a private company with limited public information, the investment opportunity carries significant uncertainty typical of early-stage biotech ventures.

Upcoming Catalysts (preview)

• Q1 2026Series A funding round closure75% success
• Q2 2026Strategic partnership with a top-20 pharma company for antibody discovery60% success
• Q3 2025Publication of validation data in a high-impact journal85% success